AUTHOR OF THIS BLOG

DR ANTHONY MELVIN CRASTO, WORLDDRUGTRACKER

Mitsubishi Tanabe Pharma Corp. and Daiichi Sankyo Co. Ltd., announced that Mitsubishi Tanabe Pharma has received approval to manufacture and market the SGLT2 inhibitor, Canaglu tablets (canagliflozin hydrate) 100 mg in Japan

 japan  Comments Off on Mitsubishi Tanabe Pharma Corp. and Daiichi Sankyo Co. Ltd., announced that Mitsubishi Tanabe Pharma has received approval to manufacture and market the SGLT2 inhibitor, Canaglu tablets (canagliflozin hydrate) 100 mg in Japan
Jul 082014
 

 

 

NEWS

Diabetes Drug Receives MMA in Japan

Mitsubishi Tanabe Pharma Corp. and Daiichi Sankyo Co. Ltd., announced that Mitsubishi Tanabe Pharma has received approval to manufacture and market the SGLT2 inhibitor, Canaglu tablets (canagliflozin hydrate) 100 mg in Japan, for the treatment of patients with type 2 diabetes mellitus. Read more…

http://www.dddmag.com/news/2014/07/diabetes-drug-receives-mma-japan?et_cid=4034150&et_rid=523035093&type=headline

FULL STORY
Share
Follow

Get every new post on this blog delivered to your Inbox.

Join other followers: